| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10722456 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US10799517 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US9949990 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US9795620 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US9572819 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US10376527 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
Elyxyb is owned by Bdsi.
Elyxyb contains Celecoxib.
Elyxyb has a total of 6 drug patents out of which 0 drug patents have expired.
Elyxyb was authorised for market use on 05 May, 2020.
Elyxyb is available in solution;oral dosage forms.
Elyxyb can be used as acute treatment of migraine with or without aura in adults.
The generics of Elyxyb are possible to be released after 27 May, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | May 5, 2023 |
Drugs and Companies using CELECOXIB ingredient
Market Authorisation Date: 05 May, 2020
Treatment: Acute treatment of migraine with or without aura in adults
Dosage: SOLUTION;ORAL
ELYXYB family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic